Literature DB >> 8068507

Etiopathogenesis of ankylosing spondylitis and reactive arthritis.

R D Inman1, R H Scofield.   

Abstract

In ankylosing spondylitis and reactive arthritis, an interplay of microbe and major histocompatibility complex initiates a sequence of events resulting in chronic inflammation. With the use of molecular probes as direct evidence and immune response patterns as indirect evidence, a strong case has been made for a central role of local microbial antigen in reactive arthritis. Cofactors such as gender, persistent gut inflammation, and antibiotic treatment may contribute to this process. Studies of transgenic rats and of familial spondylitis implicate B27 itself as the critical host variable. The results of recent studies point to intimate B27-bacteria interrelationships. HLA-B27 and proteins from enteric bacteria are structurally related, in a manner that may affect T cell response to enteric pathogens. B27 also may directly affect host-microbe interactions by modulating the invasive potential of these bacteria into target cells. Studies are in progress to apply the predictions of these in vitro systems to the in vivo situations of these diseases. The insights of research in the spondyloarthropathies may find broad applications in the rheumatic diseases.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8068507     DOI: 10.1097/00002281-199407000-00003

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  2 in total

1.  Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats.

Authors:  H C Rath; H H Herfarth; J S Ikeda; W B Grenther; T E Hamm; E Balish; J D Taurog; R E Hammer; K H Wilson; R B Sartor
Journal:  J Clin Invest       Date:  1996-08-15       Impact factor: 14.808

2.  The Importance of HLA-B27 in the Evolution of Reactive Arthritis.

Authors:  S Bănicioiu-Covei; A F Vreju; A Rosu; P L Ciurea
Journal:  Curr Health Sci J       Date:  2019-12-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.